SynthesisFrontiers in immunology2025

Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.

Fan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.